ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 401

Association of Anti-Thyroid Autoantibodies with Fibromyalgia in Rheumatoid Arthritis

Jowairiyya Ahmad1, Helena Blumen2, Claudene George3, Asha Shrestha4 and Clement Tagoe5, 1Geriatrics, Albert Einstein College of Medicine/Montefiore Medical Centre, Bronx, NY, 2Geriatrics, Albert Einstein College of Medicine, Bronx, NY, 3Geriatrics, Albert Einstein College of Medicine/Montefiore Medical centre, Bronx, NY, 4Rheumatology, Albert Einstein College of Medicine/Montefiore Medical Centre, Bronx, NY, 5Rheumatology, Albert Einsetin College of Medicine/Montefiore Medical Centre, Bronx, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Autoimmunity, Chronic pain, fibromyalgia, rheumatoid arthritis (RA) and spine involvement

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity

Session Type: Abstract Submissions (ACR)

Background/Purpose

Autoimmune thyroiditis has been linked independently with fibromyalgia and chronic widespread pain. We studied how the presence of autoimmune thyroiditis affects the clinical presentation of rheumatoid arthritis with particular reference to chronic pain syndromes

Methods

We studied a cohort of 203 patients with a diagnosis of rheumatoid arthritis for whom the presence or absence of autoimmune thyroid antibodies was documented. The relationships between thyroid autoantibodies and the presence fibromyalgia and chronic widespread pain were examined. Logistic regression analyses were performed to determine the statistical significance of these associations.

Results

In our sample of 203 patients, we identified 34% of patients who tested positive for anti-thyroid peroxidase antibodies (anti-TPO).  Thirty five percent of patients tested positive for anti-thyroglobulin antibodies (anti-TG). Among the thyroid autoantibody-positive patients, 37 % had a diagnosis of fibromyalgia or chronic widespread pain. Additional patient variables considered included age, sex, body mass index (BMI) and the presence of comorbidities, including type II diabetes.

Logistic regression analyses (adjusted by age, sex, diabetes and BMI) indicated that anti-TPO positive patients were more likely to be diagnosed with fibromyalgia and report the presence of chronic widespread pain, with an odds ratio of 3.42, 95% CI (1.665-7.017), p <.001. The odds ratio between anti-TG and fibromyalgia was not significant, p >.05. Patients who were either anti-TPO or anti-TG positive were more likely to be diagnosed with fibromyalgia with an odds ratio of 2.70, CI (1.193-6.082), p<.05.

When adjusted for degenerative disc disease, patients who were either anti-TPO or anti-TG positive were more likely to be diagnosed with fibromyalgia with an odds ratio of 2.508, CI (1.094-5.749), p<.05. Similarly patients with anti-TPO were more likely to have fibromyalgia with an adjusted OR of 3.356, CI (1.608-7.003), p <.05.  

Conclusion

There is a strong positive association between the presence of anti-thyroid autoantibodies and hence autoimmune thyroiditis, with fibromyalgia syndrome and chronic widespread pain in patients with established rheumatoid arthritis


Disclosure:

J. Ahmad,
None;

H. Blumen,
None;

C. George,
None;

A. Shrestha,
None;

C. Tagoe,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-anti-thyroid-autoantibodies-with-fibromyalgia-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology